Exploiting the DNA Damage Response for Prostate Cancer Therapy
Cancers · 23.12.2023 · 16 (1) · 83
DOI: 10.3390/cancers16010083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.12.2023. Verfasst von Travis H Stracker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 313 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, NCI-NIH intramural funding.
Abstract (Originalsprache)
Prostate cancers that progress despite androgen deprivation develop into castration-resistant prostate cancer, a fatal disease with few treatment options. In this review, we discuss the current understanding of prostate cancer subtypes and alterations in the DNA damage response (DDR) that can predispose to the development of prostate cancer and affect its progression. We identify barriers to conventional treatments, such as radiotherapy, and discuss the development of new therapies, many of which target the DDR or take advantage of recurring genetic alterations in the DDR. We place this in the context of advances in understanding the genetic variation and immune landscape of CRPC that could help guide their use in future treatment strategies. Finally, we discuss several new and emerging agents that may advance the treatment of lethal disease, highlighting selected clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Travis H Stracker, Oloruntoba I Osagie, Freddy E Escorcia, Deborah E Citrin
Förderung
- Intramural NIH HHS
- NIH HHS
- NCI-NIH intramural funding
Zitieren
APA
Stracker, T. H., Osagie, O. I., Escorcia, F. E., & Citrin, D. E. (2023). Exploiting the DNA Damage Response for Prostate Cancer Therapy. Cancers, 16(1), 83. https://doi.org/10.3390/cancers16010083
Vancouver
Stracker TH, Osagie OI, Escorcia FE, Citrin DE. Exploiting the DNA Damage Response for Prostate Cancer Therapy. Cancers. 2023;16(1):83. doi:10.3390/cancers16010083
BibTeX
@article{Stracker2023,
author = {Stracker, Travis H and Osagie, Oloruntoba I and Escorcia, Freddy E and Citrin, Deborah E},
title = {Exploiting the DNA Damage Response for Prostate Cancer Therapy},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {83},
doi = {10.3390/cancers16010083}
}
EUVIMED